Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 333-344

  Milrot, Elad ^a   Jackman, Anna ^a   Flescher, Eliezer ^a   Gonen, Pinhas ^a   Kelson, Itzhak ^a   Keisari, Yona ^a   Sherman, Levana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alpha radiation; Cervical cancer; Cisplatin; Combination treatments; Methyl jasmonate; Therapies for cervical cancer; X ray radiation

Indexed keywords

CISPLATIN; JASMONIC ACID METHYL ESTER; RADIUM 224;

ALPHA RADIATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; UTERINE CERVIX CANCER;

ACETATES; ALPHA PARTICLES; APOPTOSIS; CELL PROLIFERATION; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPENTANES; FEMALE; GAMMA RAYS; HUMANS; OXYLIPINS; PLANT GROWTH REGULATORS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84879552332     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9870-2     Document Type: Article

References (34)

1. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533-543
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
3. Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107(Suppl 1):S2-S5
4. DiMaio D, Liao JB (2006) Human papillomaviruses and cervical cancer. Adv Virus Res 66:125-159
5. Schiller JT, Castellsague X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26(Suppl 10):K53-K61
6. Lin K, Doolan K, Hung CF, Wu TC (2010) Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 109(1):4-24
7. Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C (2009) Novel chemotherapy approaches for cervical cancer. Cancer 115(14):3166-3180
8. Serkies K, Jassem J (2005) Chemotherapy in the primary treatment of cervical Carcinoma. Crit Rev Oncol Hematol 54(3):197-208
9. Maduro JH, Pras E, Willemse PH, de Vries EGE (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29(6):471-488
10. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-7279
11. Savarese A, Cognetti F (2003) New Drugs in the treatment of recurrent or metastatic cervical cancer. Crit Rev Oncol Hematol 48(3):323-327
12. Hougardy BM, Maduro JH, Vander Zee AGJ, Willemse PHB, deJong S, de Vries EGE (2005) Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. Lancet Oncol 6(8):589-598
13. Flescher E (2007) Jasmonates in cancer therapy. Cancer Lett 245(1-2):1-10
14. Cohen S, Flescher E (2009) Methyl jasmonate: a plant stress hormone as an anti-cancer drug. Phytochemistry 70(13-14):1600-1609
15. Rotem R, Heyfets A, Fingrut O, Blickstein D, Shaklai M, Flescher E (2005) Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res 65(5):1984-1993
16. Kniazhanski T, Jackman A, Heyfets A, Gonen P, Flescher E, Sherman L (2008) Methyl jasmonate induces cell death with mixed characteristics of apoptosis and necrosis in cervical cancer cells. Cancer Lett 271(1):34-46
17. Milrot E, Jackman A, Kniazhanski T, Gonen P, Flescher E, Sherman L (2012) Methyl jasmonate reduces the survival of cervical cancer cells and downregulates HPV E6 and E7, and survivin. Cancer Lett 319(1):31-38
18. Takimoto C, Calvo E (2005) Principles of oncologic pharmacotherapy. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds) Cancer management: a multidisciplinary approach. CMP Healthcare Media, Manhasset, pp 23-42
19. Heyfets A, Flescher E (2007) Cooperative cytotoxicity of methyl jasmonate with anti-cancer drugs and 2-deoxy-D-glucose. Cancer Lett 250(2):300-310
20. Yeruva L, Hall C, Abiodun J, Elegbede JA, Carper SW (2010) Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin. Anticancer Drugs 21(1):1-9
21. Ezekwudo D, Shashidharamurthy R, Devineni D, Bozeman E, Palaniappan R, Selvaraj P (2008) Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer Lett 270(2):277-285
22. Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I (2007) Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol 52(16):5025-5042
23. Cooks T, Arazi L, Schmidt M, MarshakG KI, Keisari Y (2008) Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms. Int J Cancer 122(7):1657-1664
24. Cooks T, Schmidt M, Bittan H, Lazarov E, Arazi L, Kelson I, Keisari Y (2009) Local control of lung derived tumors by diffusing alpha-emitting atoms released from intratumoral wires loaded with radium-224. Int J Radiat Oncol Biol Phys 74(3):966-973
25. Horev-Drori G, Cooks T, Bittan H, Lazarov E, Scmidt M, Arazi L, Efrati M, Kelson I, Keisari Y (2012) Local control of malignant pancreatic tumors by a combined treatment with intratumoral 225Radium-loaded wires releasing alpha-emitting atoms and chemotherapy. Transl Res 159(1):32-41
26. Lazarov E, Arazi L, Efrati M, Crooks T, Scmidt M, Keisari Y, Kelson I (2012) Comparative in vitro microdosimetric study of murine-and human-derived cancer cells exposed to alpha particles. Radiat Res 177(3):280-287
27. Alfandari J, Shnitman Magal S, Jackman A, Schlegel R, Gonen P, Sherman L (1999) HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 257(2):383-396
28. Zhao L, Wientjes MG, Au JL (2004) Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram and combination index analyses. Clin Cancer Res 10(23):7994-8004
29. Cullen KJ, Yang Z, Schumaker L, Guo Z (2007) Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 39(1):43-50
30. Ahamad A, Jhingran A (2004) New radiation techniques in gynecological cancer. Int J Gynecol Cancer 14(4):569-579
31. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394(6690):287-291
32. Katzung BG (1998) Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, analgesics, and drugs nonopioid used in gout. In: Katzung BG (ed) Basic and clinical pharmacology. Appleton & Lange, Stamford (CT), pp 578-602
33. Pouget JP, Mather SJ (2001) General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med 28(4):541-561
34. Mori E, Takahashi A, Yamakawa N, Kirita T, Ohnishi T (2009) High LET heavy ion radiation induces p53-independent apoptosis. J Radiat Res 50(1):37-42